Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 67,741 Shares

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Daljit Singh Aurora sold 67,741 shares of the business’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $1.51, for a total transaction of $102,288.91. Following the transaction, the insider owned 48,750 shares in the company, valued at $73,612.50. This trade represents a 58.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Daljit Singh Aurora also recently made the following trade(s):

• On Thursday, August 20th, Daljit Singh Aurora sold 66,711 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.51, for a total transaction of $100,733.61.
• On Friday, August 21st, Daljit Singh Aurora sold 21,055 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.60, for a total value of $33,688.00.
• On Friday, August 21st, Daljit Singh Aurora sold 20,553 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.59, for a total value of $32,679.27.
• On Wednesday, August 19th, Daljit Singh Aurora sold 30,918 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.65, for a total transaction of $51,014.70.
• On Wednesday, August 19th, Daljit Singh Aurora sold 31,000 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.65, for a total transaction of $51,150.00.
• On Monday, August 17th, Daljit Singh Aurora sold 55,016 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.50, for a total value of $82,524.00.
• On Monday, August 17th, Daljit Singh Aurora sold 91,690 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.50, for a total transaction of $137,535.00.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,987 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.59, for a total value of $55,629.33.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,162 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.58, for a total transaction of $53,975.96.

Neumora Therapeutics Stock Performance

Shares of NMRA stock traded up $0.12 during trading hours on Friday, reaching $1.63. 498,604 shares of the company’s stock were exchanged, compared to its average volume of 765,644. The company has a debt-to-equity ratio of 1.19, a quick ratio of 5.09 and a current ratio of 4.50. Neumora Therapeutics, Inc. has a fifty-two week low of $0.83 and a fifty-two week high of $3.65. The stock’s 50 day moving average is $1.60 and its 200-day moving average is $2.10.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Friday, August 14th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.01. On average, analysts expect that Neumora Therapeutics, Inc. will post -0.85 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Invesco Ltd. raised its stake in shares of Neumora Therapeutics by 151.1% in the 1st quarter. Invesco Ltd. now owns 123,655 shares of the company’s stock worth $124,000 after buying an additional 74,406 shares in the last quarter. AQR Capital Management LLC acquired a new stake in shares of Neumora Therapeutics during the 1st quarter valued at about $463,000. Russell Investments Group Ltd. boosted its holdings in Neumora Therapeutics by 2,898.1% in the second quarter. Russell Investments Group Ltd. now owns 73,812 shares of the company’s stock worth $56,000 after purchasing an additional 71,350 shares in the last quarter. Marshall Wace LLP acquired a new position in Neumora Therapeutics during the second quarter valued at approximately $183,000. Finally, Federated Hermes Inc. increased its position in Neumora Therapeutics by 10.4% in the 2nd quarter. Federated Hermes Inc. now owns 314,119 shares of the company’s stock worth $230,000 after buying an additional 29,543 shares during the period. 47.65% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Royal Bank Of Canada cut their price target on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Needham & Company LLC decreased their price target on Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, June 16th. Wall Street Zen raised Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings cut shares of Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Neumora Therapeutics in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Neumora Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $6.57.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.